Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM: Agalsidase beta switch study
NCT01650779Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2012
- Primary completion
- Mar 2013
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Started Apr 2012; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01650779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650779.